MXPA02012244A - 1-aminoalquilciclohexanos como 5-ht3 y antagonistas de receptor nicotinico neuronal. - Google Patents

1-aminoalquilciclohexanos como 5-ht3 y antagonistas de receptor nicotinico neuronal.

Info

Publication number
MXPA02012244A
MXPA02012244A MXPA02012244A MXPA02012244A MXPA02012244A MX PA02012244 A MXPA02012244 A MX PA02012244A MX PA02012244 A MXPA02012244 A MX PA02012244A MX PA02012244 A MXPA02012244 A MX PA02012244A MX PA02012244 A MXPA02012244 A MX PA02012244A
Authority
MX
Mexico
Prior art keywords
nicotinic receptor
alkylcyclohexanes
amino
aminoalkylcyclohexanes
serotoninergic
Prior art date
Application number
MXPA02012244A
Other languages
English (en)
Inventor
Aigars Jirgensons
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of MXPA02012244A publication Critical patent/MXPA02012244A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Algunos 1-aminoalquilciclohexanos son antagonistas de los receptores 5-HT3 y nicotinicos, activos de manera sistemica, son utiles en la inhibicion o progreso o en el alivio de condiciones que resultan de alteraciones de la transmision serotoninergica o nicotinergica lo que les proporciona una amplia gama de utilidad en el tratamiento de desordenes del SNC. Se proporcionan composiciones farmaceuticas de los mismos para tal proposito e igualmente se describen metodos para su elaboracion asi como un metodo para tratar condiciones que se alivian mediante la utilizacion del antagonista receptor de 5HT3 o neuronal nicotinico.
MXPA02012244A 2000-06-20 2001-06-19 1-aminoalquilciclohexanos como 5-ht3 y antagonistas de receptor nicotinico neuronal. MXPA02012244A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59710200A 2000-06-20 2000-06-20
PCT/EP2001/006964 WO2001098253A2 (en) 2000-06-20 2001-06-19 1-amino-alkylcyclohexanes as 5-ht3 and neuronal nicotinicreceptor antagonists

Publications (1)

Publication Number Publication Date
MXPA02012244A true MXPA02012244A (es) 2004-09-06

Family

ID=24390098

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02012244A MXPA02012244A (es) 2000-06-20 2001-06-19 1-aminoalquilciclohexanos como 5-ht3 y antagonistas de receptor nicotinico neuronal.

Country Status (21)

Country Link
US (2) US20070105961A1 (es)
EP (2) EP1303477A2 (es)
JP (1) JP4159351B2 (es)
KR (1) KR100570374B1 (es)
CN (1) CN1307147C (es)
AR (1) AR032756A1 (es)
AU (2) AU2001281861B2 (es)
CA (1) CA2410852C (es)
CZ (1) CZ2003497A3 (es)
EA (1) EA006067B1 (es)
GE (1) GEP20053431B (es)
HK (1) HK1076276A1 (es)
HU (1) HUP0301551A3 (es)
IL (2) IL153480A0 (es)
MX (1) MXPA02012244A (es)
NO (1) NO329491B1 (es)
PL (1) PL359583A1 (es)
TW (1) TW593223B (es)
UA (1) UA74194C2 (es)
WO (1) WO2001098253A2 (es)
ZA (1) ZA200104187B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
TW200306189A (en) 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
KR100777904B1 (ko) * 2002-10-24 2007-11-28 메르츠 파마 게엠베하 운트 코. 카가아 1-아미노시클로헥산 유도체 및 아세틸콜린에스테라제 저해제를 포함하는 약학적 제품 및 이를 이용한 복합 치료
EP2260844A1 (en) 2003-05-27 2010-12-15 Merz Pharma GmbH & Co. KGaA Combination of an NMDA Receptor Antagonist and a Selective Serotonin Reuptake Inhibitor for the Treatment of Depression and other Mood Disorders
WO2005009421A2 (en) * 2003-07-28 2005-02-03 Merz Pharma Gmbh & Co. Kgaa The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
CN101389315A (zh) * 2004-06-17 2009-03-18 莫茨药物股份两合公司 美金刚口服剂型即释制剂
WO2006078239A1 (en) 2005-01-18 2006-07-27 University Of Florida Compositions and methods for inhibiting pain
BRPI0922057A2 (pt) 2008-11-19 2015-12-15 Envivo Pharmaceuticals Inc tratamento dos transtorno cognitivos com (r)-7-cloro-n-(quiniclidin-3-il)benzo[b]tiofeno-2-carboxamida e sais farmeceuticamente aceitaveis do mesmo
TWI432188B (zh) * 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
CN102159201A (zh) 2008-12-19 2011-08-17 莫茨药物股份两合公司 用于治疗肥大细胞介导的疾病的1-氨基-烷基环己烷衍生物
RS56812B1 (sr) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc Farmaceutske formulacije koje sadrže kristalne oblike (r)-7-hloro-n-(kinuklidin-3-il)benzo(b)tiofen-2-karboksamid hidrohlorid monohidrata
WO2013169646A1 (en) 2012-05-08 2013-11-14 Envivo Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411955D0 (en) * 1994-06-15 1994-08-03 Merck Sharp & Dohme Therapeutic agents
US5886051A (en) * 1995-11-08 1999-03-23 University Of Florida Research Foundation, Inc. Methods and compositions for the treatment of neurodegeneration
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
US6436946B1 (en) * 1997-05-02 2002-08-20 Morris A. Mann Xanthine-containing compositions for oral administration and uses related thereto
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
CN1136187C (zh) * 1997-06-30 2004-01-28 莫茨股份公司 1-氨基烷基环己烷nmda受体拮抗剂
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
AR016212A1 (es) * 1998-04-28 2001-06-20 Astra Ab Uso de compuestos farmaceuticos que tienen una actividad antagonista de nmda para preparar un medicamento para el tratamiento del sindrome de intestino irritable (ibs), y composiciones farmaceuticas
US6139861A (en) * 1999-01-14 2000-10-31 Friedman; Mark Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists

Also Published As

Publication number Publication date
KR100570374B1 (ko) 2006-04-24
AU2001281861B2 (en) 2006-08-17
AU8186101A (en) 2002-01-02
CZ2003497A3 (cs) 2004-08-18
NO20026103L (no) 2003-02-19
EA200300040A1 (ru) 2003-06-26
HUP0301551A2 (hu) 2003-11-28
JP2004501130A (ja) 2004-01-15
CN1620419A (zh) 2005-05-25
EP1303477A2 (en) 2003-04-23
GEP20053431B (en) 2005-01-25
PL359583A1 (en) 2004-08-23
HK1076276A1 (en) 2006-01-13
HUP0301551A3 (en) 2005-04-28
US20070105961A1 (en) 2007-05-10
IL153480A (en) 2007-08-19
EA006067B1 (ru) 2005-08-25
IL153480A0 (en) 2003-07-06
EP2277850A1 (en) 2011-01-26
KR20030053475A (ko) 2003-06-28
AR032756A1 (es) 2003-11-26
CA2410852C (en) 2007-04-24
TW593223B (en) 2004-06-21
UA74194C2 (uk) 2005-11-15
WO2001098253A2 (en) 2001-12-27
ZA200104187B (en) 2002-11-22
NO20026103D0 (no) 2002-12-19
JP4159351B2 (ja) 2008-10-01
US20100298442A1 (en) 2010-11-25
NO329491B1 (no) 2010-10-25
CA2410852A1 (en) 2001-12-27
WO2001098253A3 (en) 2002-04-25
CN1307147C (zh) 2007-03-28

Similar Documents

Publication Publication Date Title
MXPA02012244A (es) 1-aminoalquilciclohexanos como 5-ht3 y antagonistas de receptor nicotinico neuronal.
RS20050199A (en) Imidazolopyridines and methods of making and using the same
MXPA05008524A (es) Pirazoles y metodos de elaboracion y uso de los mismos.
WO2004020599A3 (en) Hedgehog antagonists, methods and uses related thereto
IL114599A (en) Substituted pyrimidine compounds their preparation and pharmaceutical compositions containg them
CA2292558A1 (en) 1-amino-alkylcyclohexane nmda receptor antagonists
RS95904A (en) Tri -substituted heteroaryls and methods for making and using the same
HK1068136A1 (en) Muscarinic antagonists
WO2002030462A3 (en) Hedgehog antagonists, methods and uses related thereto
CA2515946A1 (en) Use of palonosetron treating post-operative nausea and vomiting
WO2003028641A3 (en) Mch receptor antagonists
TW200508224A (en) Cyclic derivatives as modulators of chemokine receptor activity
NO20060719L (no) Substituerte cykloalkylaminderivater som modulatorer av kemokin reseptor aktivitet
WO2001066534A3 (en) Cyclic and bicyclic diamino histamine-3 receptor antagonists
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
WO2004091514A3 (en) Cgrp receptor antagonists
RS20060250A (en) 1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, method for the production thereof, and their use as antiphlogistics
PL343467A1 (en) Heterocyclically substituted amides, their production and their use
ATE240958T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
WO2005079464A3 (en) Vitamin d receptor antagonists and their use in treating asthma
MXPA04004477A (es) Antagonistas del neuropeptido neuroquinina-1(nk1).
CA2505990A1 (en) Palonosetron for the treatment of chemotherapy-induced emesis
NO20004502D0 (no) Nye sammensetninger av eprosartan
CA2465738A1 (en) Unsaturated 1-amino-alkylcyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonists
HK1056725A1 (en) 2-Thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry.

Legal Events

Date Code Title Description
FG Grant or registration